Panaxium

Panaxium is a bioelectronic medicine company based in Toronto, Canada, with additional roots in Aix-en-Provence, France. Founded by Dr. Brad Schmidt and Pierre Leleux, the company focuses on developing precision therapies for neurological recovery through advanced AI-enabled iontronic devices. Their mission is to transform the treatment of neurological diseases by integrating microscale iontronic technologies with various scientific disciplines. The core product of Panaxium is a brain-machine interface (BMI) designed for surgeons and neurologists. This innovative device allows for direct intervention in neurological injuries, facilitating targeted treatment and patient recovery. Currently, the BMI is in preclinical work and human clinical trials, with investigations led by Dr. Gilles Huberfeld in Paris. Panaxium's team includes renowned scientists and clinical advisors from prestigious institutions, highlighting their strong collaborations in research and clinical development. The company has received significant funding to support its initiatives and has been recognized with awards for its innovative approach to neuromodulation therapies.

• Employees 17
• Founded 2016